相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer
Yang Xiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
Hailong Ma et al.
MOLECULAR CANCER (2020)
SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms
Cheng Lin Xu et al.
NUCLEIC ACIDS RESEARCH (2020)
Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma Genetic Classification and Its Implications for Prognosis and Treatment
Jennifer L. Crombie et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme
Hsun-Hua Lee et al.
CANCERS (2020)
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2
Namrata Bora-Singhal et al.
SCIENTIFIC REPORTS (2020)
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge
David Michael Abbott et al.
CANCERS (2020)
Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction
Brianna Burke et al.
FRONTIERS IN ONCOLOGY (2020)
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma
Wuming Wang et al.
FRONTIERS IN PHARMACOLOGY (2020)
HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
Trang Thi Thu Nguyen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
The application of histone deacetylases inhibitors in glioblastoma
Rui Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Hirva Mamdani et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer
Xue-ting Hu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma
Ting Han et al.
CANCER BIOLOGY & MEDICINE (2020)
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion
Runhui Zheng et al.
CASE REPORTS IN HEMATOLOGY (2020)
P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer
Dahong Yao et al.
THERANOSTICS (2020)
Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy
Michael I. Koukourakis et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2019)
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Aikaterini F. Giannopoulou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells
Umamaheswari Natarajan et al.
MEDICINA-LITHUANIA (2019)
Childhood cerebellar tumours mirror conserved fetal transcriptional programs
Maria C. Vladoiu et al.
NATURE (2019)
HDAC inhibitors tested in phase III trial
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells
Olga Pastorino et al.
CANCERS (2019)
New Functions of Long Noncoding RNAs during EMT and Tumor Progression
Chunlai Li
CANCER RESEARCH (2019)
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
Jan J. Bandolik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang et al.
LANCET ONCOLOGY (2019)
The histone variant H2A.Z in gene regulation
Benedetto Daniele Giaimo et al.
EPIGENETICS & CHROMATIN (2019)
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells
Corrado Caslini et al.
ONCOGENE (2019)
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
DRUG SAFETY (2019)
Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2
Renske J. E. van den Bijgaart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Halina Was et al.
CLINICAL EPIGENETICS (2019)
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia
S. Tharkar-Promod et al.
LEUKEMIA (2018)
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications
Parunya Chaiyawat et al.
MODERN PATHOLOGY (2018)
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
Evanthia Galanis et al.
NEURO-ONCOLOGY (2018)
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
Linlin Liu et al.
BIOSCIENCE REPORTS (2018)
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Michael J. Duffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Functional Classification and Experimental Dissection of Long Noncoding RNAs
Florian Kopp et al.
CELL (2018)
Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
Yiru Zhang et al.
CLINICAL CANCER RESEARCH (2018)
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity
Ahmed T. Negmeldin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Jooeun Bae et al.
LEUKEMIA (2018)
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Navin Pinto et al.
PEDIATRIC BLOOD & CANCER (2018)
A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti- tumor Ability in Human Cancer Cells in Vitro and in Vivo
Yi-Wen Wu et al.
FRONTIERS IN PHARMACOLOGY (2018)
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Marta Di Martile et al.
ONCOGENESIS (2018)
Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress
Ying Huang et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2018)
Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes
Anubama Rajan et al.
SCIENTIFIC REPORTS (2018)
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy
Marcella La Noce et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Genome-wide characterization of lncRNAs in acute myeloid leukemia
Lijun Lei et al.
BRIEFINGS IN BIOINFORMATICS (2018)
Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells
Viviane Rosner Almeida et al.
MOLECULAR NEUROBIOLOGY (2017)
Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects
M. Janaki Ramaiah et al.
GENE (2017)
Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
Douglas W. Sborov et al.
LEUKEMIA & LYMPHOMA (2017)
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio et al.
ONCOTARGET (2017)
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression
Petko Fiziev et al.
CELL REPORTS (2017)
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Roberta Mazzone et al.
CLINICAL EPIGENETICS (2017)
Real-world evidence in the treatment of ovarian cancer
E. A. Eisenhauer
ANNALS OF ONCOLOGY (2017)
The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity
Ahmed T. Negmeldin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells
Fatima Liliana Monteiro et al.
CANCER LETTERS (2017)
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Sridhar Murahari et al.
BMC CANCER (2017)
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Clare M. Adams et al.
CANCER RESEARCH (2016)
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma
Mei-Chuan Chen et al.
ONCOTARGET (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma
Chatla Srinivas et al.
APOPTOSIS (2016)
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
John A. Halsall et al.
BIOESSAYS (2016)
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma
Yanxin Pei et al.
CANCER CELL (2016)
Molecular mechanism leading to SAHA-induced autophagy in tumor cells: evidence for a p53-dependent pathway
Leopold F. Froehlich et al.
CANCER CELL INTERNATIONAL (2016)
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation
Lianmin Bao et al.
CELL BIOLOGY AND TOXICOLOGY (2016)
How do tumor cells respond to HDAC inhibition?
Andrea Newbold et al.
FEBS JOURNAL (2016)
Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation
Zhantao Deng et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP
Jing Liu et al.
TRANSLATIONAL ONCOLOGY (2016)
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
Leslie A. Garrett et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Novel Mechanisms of Regulation of miRNAs in CLL
Veronica Balatti et al.
TRENDS IN CANCER (2016)
Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents
Michiel Kroesen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2015)
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
Saira R. Ali et al.
DRUG DEVELOPMENT RESEARCH (2015)
Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development
Marta Maleszewska et al.
FUTURE ONCOLOGY (2015)
Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma
Milcah C. Scott et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells
Tsung-Hua Hsieh et al.
MOLECULAR THERAPY (2015)
The landscape of long noncoding RNAs in the human transcriptome
Matthew K. Iyer et al.
NATURE GENETICS (2015)
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation
Chiara Pastori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation
I. Rettig et al.
CELL DEATH & DISEASE (2015)
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors
Joseph J. Sacco et al.
ONCOTARGET (2015)
The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
Xiaodong Mu et al.
BIOMED RESEARCH INTERNATIONAL (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Long non-coding RNAs in cancer invasion and metastasis
Xiao-han Shen et al.
MODERN PATHOLOGY (2015)
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
Valerie B. Sampson et al.
PLOS ONE (2015)
Epigenetics of cancer stem cells: Pathways and therapeutics
Samriddhi Shukla et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2014)
miRNA biogenesis: Biological impact in the development of cancer
Sandra L. Romero-Cordoba et al.
CANCER BIOLOGY & THERAPY (2014)
Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma
Jozef Ban et al.
CANCER RESEARCH (2014)
Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Savita Sankar et al.
CLINICAL CANCER RESEARCH (2014)
SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells
Hongpeng He et al.
GENE (2014)
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
Kwai Fung Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype
Nicoletta Fortunati et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Bertrand Coiffier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Olivia S. Chao et al.
MOLECULAR CANCER RESEARCH (2014)
Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia
Rocio Juarez-Velazquez et al.
LEUKEMIA & LYMPHOMA (2014)
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
Pamela V. Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells
Dong-Qin Chen et al.
ONCOTARGET (2014)
Control of Transcriptional Elongation
Hojoong Kwak et al.
ANNUAL REVIEW OF GENETICS, VOL 47 (2013)
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors
Don W. Coulter et al.
ANTI-CANCER DRUGS (2013)
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
P. A. Cassier et al.
BRITISH JOURNAL OF CANCER (2013)
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Stacey M. Frumm et al.
CHEMISTRY & BIOLOGY (2013)
The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Krithi Rao-Bindal et al.
CURRENT CANCER DRUG TARGETS (2013)
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells
Linda Marek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
Filippo de Marinis et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Activation of p21 by HDAC Inhibitors Requires Acetylation of H2A.Z
Luca Bellucci et al.
PLOS ONE (2013)
Histone deacetylase 10 promotes autophagy-mediated cell survival
Ina Oehme et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Retinoids induce stem cell differentiation via epigenetic changes
Lorraine J. Gudas
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2013)
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers
Guenter Niegisch et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Epigenetic Upregulation of IncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB
Angela Garding et al.
PLOS GENETICS (2013)
Lung cancer: potential targets for immunotherapy
Eric Tartour et al.
LANCET RESPIRATORY MEDICINE (2013)
Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells
Yanfang Li et al.
FRONTIERS IN ONCOLOGY (2013)
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer
Jhanelle Gray et al.
CANCER BIOLOGY & THERAPY (2012)
Causes and Consequences of MicroRNA Dysregulation
Marilena V. Iorio et al.
CANCER JOURNAL (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown et al.
CLINICAL CANCER RESEARCH (2012)
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
Benigno C. Valdez et al.
EXPERIMENTAL HEMATOLOGY (2012)
Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer
Qiao Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment
Till Milde et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Amila Suraweera et al.
MOLECULAR CELL (2012)
Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans
Karen Adelman et al.
NATURE REVIEWS GENETICS (2012)
Histone H2A variants in nucleosomes and chromatin: more or less stable?
Clemens Boenisch et al.
NUCLEIC ACIDS RESEARCH (2012)
HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)
Mehdi Ouaissi et al.
PANCREATOLOGY (2012)
Targeting Immune Checkpoints Releasing the Restraints on Anti-Tumor Immunity for Patients With Melanoma
Michael A. Postow et al.
CANCER JOURNAL (2012)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
Seung Joon Lee et al.
BMC CANCER (2011)
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
Cao Yang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Leonardo Salmena et al.
CELL (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia
Muller Fabbri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E
Matan Ofir et al.
MOLECULAR CANCER RESEARCH (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells
Dara Nalls et al.
PLOS ONE (2011)
The Emergence of lncRNAs in Cancer Biology
John R. Prensner et al.
CANCER DISCOVERY (2011)
SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability
Glenn M. Marshall et al.
PLOS GENETICS (2011)
Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells
P. Wu et al.
CELL DEATH AND DIFFERENTIATION (2010)
HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity
Vivek Sharma et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma Preclinical Rationale and Clinical Trials
Paul K. Paik et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589
John Kauh et al.
PLOS ONE (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung
Yoshihiro Minamiya et al.
TUMOR BIOLOGY (2010)
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Daniel Finley
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Histones: Annotating Chromatin
Eric I. Campos et al.
ANNUAL REVIEW OF GENETICS (2009)
Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome on HDAC Inhibitor-Induced Apoptosis
Susan Fotheringham et al.
CANCER CELL (2009)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Ina Oehme et al.
CLINICAL CANCER RESEARCH (2009)
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
Fabian Vandermeers et al.
CLINICAL CANCER RESEARCH (2009)
High-resolution human core-promoter prediction with CoreBoost_HM
Xiaowo Wang et al.
GENOME RESEARCH (2009)
Histone deacetylase inhibitors: Anticancer compounds
Karen T. Smith et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Targeting histone deacetylases for the treatment of disease
M. W. Lawless et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities
Gabriella Ortore et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2009)
13-cis Retinoic Acid Treatment of a Patient With Chemotherapy Refractory Nephroblastomatosis
Olaf Witt et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Mitchell Guttman et al.
NATURE (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
Ya-Ting Yang et al.
NEOPLASIA (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue:: class II and IV are hypoexpressed in glioblastomas
Agda Kb Lucio-Eterovic et al.
BMC CANCER (2008)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
Sun-Mi Park et al.
GENES & DEVELOPMENT (2008)
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway
A. Hrzenjak et al.
JOURNAL OF PATHOLOGY (2008)
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
Qun Zhou et al.
MOLECULAR CANCER RESEARCH (2008)
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Noam Stern-Ginossar et al.
NATURE IMMUNOLOGY (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase
Jung-Hyun Park et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors
Mirjam T. Epping et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells
Juergen Sonnemann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitors regulate retinoic acid receptor β expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms
Maxy De los Santos et al.
MOLECULAR ENDOCRINOLOGY (2007)
LIF- and IL-6-Induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation
Norihiko Ohbayashi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
miR-200b mediates post-transcriptional repression of ZFHX1B
Nanna Ronbjerg Christoffersen et al.
RNA (2007)
Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin
Gregory J. Hurteau et al.
CANCER RESEARCH (2007)
Roles of aurora kinases in mitosis and tumorigenesis
Jingyan Fu et al.
MOLECULAR CANCER RESEARCH (2007)
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Paola Gallinari et al.
CELL RESEARCH (2007)
Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing
Kyu-Hyeon Yeom et al.
NUCLEIC ACIDS RESEARCH (2006)
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D. A. Richards et al.
ANNALS OF ONCOLOGY (2006)
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1
Y Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins
E Michishita et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
DNA methylation and histone modifications: teaming up to silence genes
F Fuks
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
The transcriptional landscape of the mammalian genome
P Carninci et al.
SCIENCE (2005)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors
MV Blagosklonny et al.
CANCER RESEARCH (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions
C Vandewalle et al.
NUCLEIC ACIDS RESEARCH (2005)
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
GA Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase:: role of Bcl-xL down-regulation
H Neuzil et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells
MS Roh et al.
APOPTOSIS (2004)
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases
JR Somoza et al.
STRUCTURE (2004)
Aurora-kinase inhibitors as anticancer agents
N Keen et al.
NATURE REVIEWS CANCER (2004)
Docking and scoring in virtual screening for drug discovery: Methods and applications
DB Kitchen et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Principles for modulation of the nuclear receptor superfamily
H Gronemeyer et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The Sir2 family of protein deacetylases
G Blander et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
OH Krämer et al.
EMBO JOURNAL (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
The human silent information regulator NO homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase
B Schwer et al.
JOURNAL OF CELL BIOLOGY (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma
XBX Cao et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase
H Vaziri et al.
CELL (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Deacetylation of p53 modulates its effect on cell growth and apoptosis
JY Luo et al.
NATURE (2000)
分享论文
